Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages
Braz. j. med. biol. res
;
49(12): e5826, 2016. graf
Article
in English
| LILACS
| ID: biblio-828173
ABSTRACT
Glucagon-like peptide 1 (GLP-1), a kind of gut hormone, is used in the treatment of type 2 diabetes (T2D). Emerging evidence indicates that GLP-1 has anti-inflammatory activity. Chronic inflammation in the adipose tissue of obese individuals is a cause of insulin resistance and T2D. We hypothesized that GLP-1 analogue therapy in patients with T2D could suppress the inflammatory response of macrophages, and therefore inhibit insulin resistance. Our results showed that GLP-1 agonist (exendin-4) not only attenuated macrophage infiltration, but also inhibited the macrophage secretion of inflammatory cytokines including TNF-β, IL-6, and IL-1β. Furthermore, we observed that lipopolysaccharide (LPS)-induced macrophage conditioned media could impair insulin-stimulated glucose uptake. This effect was compensated by treatment with the conditioned media from macrophages treated with the combination of LPS and exendin-4. It was also observed that exendin-4 directly inhibited the activation of NF-κB in macrophages. In conclusion, our results indicated that GLP-1 improved inflammatory macrophage-derived insulin resistance by inhibiting NF-κB pathway and secretion of inflammatory cytokines in macrophages. Furthermore, our observations suggested that the anti-inflammatory effect of GLP-1 on macrophages can contribute to GLP-1 analogue therapy of T2D.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Peptides
/
Venoms
/
Insulin Resistance
/
Inflammation Mediators
/
Glucagon-Like Peptide 1
/
Inflammation
/
Macrophages
Limits:
Animals
/
Humans
Language:
English
Journal:
Braz. j. med. biol. res
Journal subject:
Biology
/
Medicine
Year:
2016
Type:
Article
/
Project document
Affiliation country:
China
Institution/Affiliation country:
Wenzhou Medical University/CN
Similar
MEDLINE
...
LILACS
LIS